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Background Arrhythmogenic left ventricular cardiomyopathy (ALVC) is a rare form of arrhythmogenic cardiomyopathy charac-
terized by fibrofatty replacement of left ventricular myocardium, malignant arrhythmia, and sudden cardiac death.
The definition incorporates several genetic causes, including pathogenic variation in the Filamin C gene (FLNC).
Although awareness of ALVC has improved, identification remains challenging and diagnostic criteria continue to
evolve.
...................................................................................................................................................................................................
Case summary A 50-year-old athletic male was admitted following an out-of-hospital cardiac arrest due to ventricular tachycardia
(VT) whilst playing football. Coronary angiography revealed unobstructed epicardial vessels and the diagnosis of
ALVC was suggested by cardiovascular magnetic resonance imaging, which demonstrated a mildly dilated and mod-
erately impaired left ventricle with epicardial late gadolinium enhancement in the basal to mid-lateral walls and sub-
endocardial septum. Initial testing with a cardiomyopathy and arrhythmia gene panel was negative but extended
testing uncovered a likely pathogenic variant in FLNC. Subsequently, the patient experienced a recurrence of sus-
tained VT necessitating implantable cardioverter-defibrillator (ICD) therapies, ultimately undergoing a combined
epicardial and endocardial VT ablation 4 years after presentation. Six months post-ablation, he was asymptomatic
and his arrhythmia rendered quiescent.
...................................................................................................................................................................................................
Discussion Arrhythmogenic cardiomyopathy should be considered in the evaluation of an initially unexplained cardiac arrest.
This case characterizes the clinical features of a patient with FLNC cardiomyopathy and emphasizes the utility of
genetic testing using modern gene panels in patients with comparable phenotypes. We also demonstrate that opti-
mal medical therapy with antiarrhythmic drugs, exercise restriction, ICD insertion, and catheter ablation can be
useful in the management of ALVC with positive outcomes
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Arrhythmogenic cardiomyopathy (ACM) is a rare heritable disorder
characterized by ventricular arrhythmia and fibrofatty replacement of
ventricular myocardium.1,2 Classically considered a disease of the
right ventricle (RV), biventricular and left ventricular ACM pheno-
types are increasingly recognized. The term ‘arrhythmogenic left ven-
tricular cardiomyopathy’ (ALVC) has since been adopted as a distinct
clinical entity within the spectrum of ACM.
Given its rarity, clinical features and outcomes of patients with
ALVC are scarce and identification can prove challenging. However,
pathogenic variants affecting Filamin C (FLNC), an essential protein
for myocyte integrity and cell signalling, have been increasingly impli-
cated in patients presenting with characteristic hallmarks of ALVC,
including LV predominant disease, malignant arrhythmia, and sudden
cardiac death.3,4 In this case report, we discuss the challenges of diag-
nosis and management in a patient who presented with cardiac arrest
and later diagnosed with ALVC.
Timeline
Learning points
• Arrhythmogenic left ventricular cardiomyopathy is a distinct form of arrhythmogenic cardiomyopathy (ACM) characterized by left
ventricular (LV) structural, electrical, and genetic abnormalities, including systolic dysfunction and arrhythmia, non-ischaemic LV late
gadolinium enhancement, left precordial T-wave inversion, low limb lead QRS voltages, and pathogenic variants in ACM-related genes.
• Phenotype-guided genetic testing can enhance diagnostic certainty, facilitate predictive testing of family members, and occasionally inform
risk stratification, such as lowering the threshold for primary prevention defibrillator implantation in patients with Filamin C.




Premorbid state Recent symptoms of exertional pre-syn-
cope; playing 5-a-side football and cycling
60–100 miles regularly
Presentation Out-of-hospital ventricular tachycardia (VT)
arrest whilst playing football
Coronary angiography: unobstructed epi-
cardial vessels
Cardiac magnetic resonance imaging: mildly
dilated left ventricle (LV) (Left ventricular
end diastolic volume 214 mL) with mod-
erately impaired LV systolic function
(LVEF 41%) and no regional wall motion
abnormalities. Non-dilated right ventricle
(RV) with preserved systolic function.
Low-grade late gadolinium enhancement
within the septum and basal lateral
subepicardium






Started Bisoprolol 5 mg o.d.
Blood sample sent for Lamin A (LMNA)
gene testing and family referred for clinic-
al screening
26 months LMNA gene studies negative
Fluorodeoxyglucose (FDG) positron emis-
sion cardiac computed tomography:
negative for sarcoid and active
inflammation
Implantable cardioverter-defibrillator (ICD)
interrogation: brief runs of non-sustained
ventricular tachycardia (NSVT) and one
appropriate shock for sustained run of
fast VT
Switched to Nadolol 80 mg b.i.d.
31 months ICD interrogation: no recorded ventricular
arrhythmia
Genetic testing performed using a panel of
77 cardiomyopathy and arrhythmia-
related genes
41 months Genetic testing unable to identify a cause
Echo: mildly dilated LV [left ventricular end-
diastolic diameter (LVEDD) 59 mm] with
mild-moderately impaired LV systolic
function (LVEF 45%). Markedly hypoki-
netic inferolateral and anterolateral walls.
Mildly dilated RV with moderately
impaired systolic function
Nadolol not tolerated due to fatigue,
changed to Sotalol 40 mg b.i.d.
Started Ramipril 1.25 mg o.d. for left ven-
tricular systolic dysfunction
42 months Two episodes of NSVT and one of fast VT (250
b.p.m.) treated by antitachycardia pacing
Increased Sotalol to 40/80 mg b.i.d.
Genetic testing to include Filamin C (FLNC)
52 months Patient tests positive for likely pathogenic
FLNC variant
Continued
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A 50-year-old Caucasian male collapsed unexpectedly whilst playing
football. He was brought to hospital following successful resuscita-
tion for an out-of-hospital ventricular tachycardia (VT) arrest. He had
no significant past medical or family history of cardiac disease and was
a keen recreational athlete, playing 5-a-side football regularly and
cycling 60–100 miles per week. In the months leading up to his car-
diac arrest, he recalled three brief episodes of exertional pre-
syncope whilst playing sports. On admission, coronary angiography
showed unobstructed epicardial vessels and echocardiography
revealed mild LV impairment with normal heart valves. An FDG
PET–computed tomography scan was negative for active myocardial
inflammation. However, cardiovascular magnetic resonance imaging
(CMRI) demonstrated a mildly dilated and moderately impaired LV
[left ventricular ejection fraction (LVEF) 41%] with epicardial late
gadolinium enhancement of the lateral wall and subendocardial en-
hancement of the septum. The RV was non-dilated with no regional
wall motion abnormalities (Figure 1) (Videos 1–3).
A diagnosis of ACM was suspected, and he received an implantable
cardiac defibrillator (ICD) for secondary prevention. Post-implant-
ation, his 12-lead electrocardiogram (ECG) showed an atrial paced
rhythm with normal ventricular conduction (Figure 2). The limb lead
complexes were of low voltage and demonstrated fractionated QRS
complexes. There were flattened inferolateral T waves and his signal-
averaged ECG was negative for late potentials. He was discharged on
Bisoprolol 5 mg daily, lifestyle advice to limit his exercise intensity,
and referred for genetic testing along with a recommendation for
clinical screening of his family members. He was asymptomatic for a
significant period, but at 26 months follow-up device interrogation
demonstrated three runs of non-sustained ventricular tachycardia
(NSVT) and he received one shock for sustained fast VT. He was
then trialled on Nadolol therapy. Genetic testing for pathogenic
Lamin A variants and subsequent testing against a panel of 77 cardio-
myopathy and arrhythmia-related genes were negative.
At 41 months, an echocardiogram demonstrated a mildly dilated
LV with mild-moderate systolic impairment (LVEF 45%).
Interrogation of his ICD revealed two episodes of NSVT and one fast
sustained VT treated by antitachycardia pacing. He was switched to
Sotalol for its Class III antiarrhythmic properties and started Ramipril
1.25 mg once daily. Given his electrical and structural phenotype,
genetic testing was extended to include FLNC. Subsequently, he
tested positive for a likely pathogenic FLNC frameshift variant
[c.8107del; p.(Asp2703ThrfsTer69)], thus confirming the diagnosis of
ALVC. Predictive testing also uncovered the variant in his three chil-
dren, all of whom had variable clinical expression of the disease.
At 52 months he was climbing a ski slope and experienced an epi-
sode of fast VT requiring an ICD shock (Figure 3). Following urgent
electrophysiology outpatient review, he was referred for VT ablation
utilizing a combined endocardial and epicardial approach. During the
procedure, two types of VT arising from the LV were readily induced
and radiofrequency ablation was targeted to abnormal local poten-
tials and the region surrounding epicardial and endocardial scar. At
6 months post-ablation, he was asymptomatic and arrhythmia free on
Sotalol 80 mg twice daily, and echocardiography showed some im-
provement in LV systolic function (LVEF 50–54%).
Discussion
Arrhythmogenic left ventricular cardiomyopathy is an under-charac-
terized phenotype of ACM and few studies have evaluated clinical
markers of the disease.5–7 The prevalence is also likely underesti-
mated as findings of LV systolic impairment and myocardial fibrosis
may overlap clinically with DCM and other ACM phenotypes. This
difficulty in characterization was addressed by a statement from the
Heart Rhythm Society,1 who proposed broadening the definition of
ACM to an ‘arrhythmogenic heart muscle disorder not explained by is-
chaemic, hypertensive, or valvular heart disease’. The recently introduced
‘Padua criteria’ propose an update from the 2010 Task Force criteria
for diagnosing ACM in order to improve differentiation between
ACM phenotypes and identification of left-sided genetic causes.8,9 It
utilizes a combination of structural, histological, electrocardiographic,
and genetic parameters along with the patient’s presentation and
family history. For a definitive diagnosis of ALVC, the patient must
have a confirmed genetic mutation in one of the genes implicated in
disease pathogenesis (Table 1).
The presenting feature in this case was an initially unexplained car-
diac arrest secondary to ventricular arrhythmia. In conjunction with
the scarring pattern on CMRI, a diagnosis of ALVC was suspected
but could not be confirmed without genetic evidence. Although car-
diovascular magnetic resonance has a fundamental role in delineating
phenotype, additional investigative modalities such as molecular gen-
etic studies, family screening, and rarely endomyocardial biopsy, may
improve diagnostic certainty. Other suggestive features of ALVC in-
clude the presence of inferolateral T-wave inversion or apparent
DCM with an arrhythmic burden incongruous with myocardial
function.7
The elusive genetic basis of this case supports evolving evidence
that the genetic architecture underlying ACM are more complex




One episode of fast VT (cycle length
220 ms) within the ventricular fibrillation
defibrillator zone whilst climbing a ski
slope, shock delivered
Increased Sotalol to 80 mg b.i.d.
Referred for VT ablation
57 months Combined epicardial and endocardial VT
ablation
58 months Echo: normal LV size and wall thickness
(LVEDD 49 mm) with mildly impaired LV
systolic function (LVEF 50–54%). Normal
RV size with impaired radial function
63 months No recurrence of arrhythmia at 6-month
follow-up post-ablation
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Figure 1 Late gadolinium enhancement cardiovascular magnetic resonance images showing horizontal long axis (four-chamber) (A) mid-ventricular
short axis (B) and left ventricular outflow tract (three-chamber) (C) views. The yellow arrows indicate regions of epicardial lateral fibrosis and the red
arrows point to septal subendocardial enhancement.
Figure 2 Twelve-lead electrocardiogram post-implantable cardioverter-defibrillator implantation demonstrating an atrial paced rhythm with
inferolateral T-wave flattening and low voltage QRS complexes in the limb leads.
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..potentially ‘outdated’ gene panels may omit newly identified genes
that are implicated in disease pathogenesis, thereby precluding a for-
mal diagnosis. Therefore, it is prudent for clinicians to have a low
threshold for broadened genetic testing in patients with a suggestive
phenotype, as seen here where the decision to extend gene testing
yielded the diagnosis of FLNC-induced ALVC. Notably, our patient’s
variant had been reported in two other patients with comparable
phenotypes.10,11
Whilst rare, ACM-associated FLNC presents with a distinctive
phenotype of abnormalities including LV dilation and myocardial fi-
brosis, systolic dysfunction, inferolateral negative T waves, low QRS
voltages, and ventricular arrhythmias,1,3,10 all of which were present
in this case. Truncating variants in FLNC have been shown to exhibit
a dominant inheritance pattern and high penetrance amongst geno-
type-positive individuals (>97% in carriers older than 40 years of
age).10 As such, extending genetic testing to family members is
Figure 3 Intracardiac implantable cardioverter-defibrillator electrograms (top channel: atrial near-field; middle channel: ventricular far-field; bottom
channel: markers) of an appropriate shock (Charge Delivered (CD) marker) for fast monomorphic ventricular tachycardia (Ventricular sensed (VS)
event marker; cycle length 220 ms) occurring within the ventricular fibrillation zone. Recurrence of ventricular tachycardia shortly after shock delivery
with intermittent Atrioventricular (AV) sequential pacing, the arrhythmia later spontaneously terminating without the requirement for additional
therapy.
Video 1 Horizontal long axis (Four-chamber view) cardiovascu-
lar magnetic resonance imaging at presentation. Video 2 Left ventricular outflow tract (3-chamber) cardiovascu-
lar magnetic resonance imaging at presentation.
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essential to allow for early intervention. Moreover, genetic testing
can occasionally enhance risk stratification and management. In lower
risk FLNC–ACM patients without a history of sustained arrhythmia,
international consensus currently supports ICD implantation in those
exhibiting moderate LV systolic impairment (LVEF < 45%).1
Overall, the aim of medical therapy in ACM is to treat arrhythmia,
optimize ventricular function, and manage symptoms.1 Exercise is
also known to accelerate disease progression and competitive sport
is associated with an increased risk of ventricular arrhythmia and
SCD.12 Several observational studies also suggest a dose-dependent
relationship between participation in endurance exercise and risk of
developing ACM in genotype-positive family members.1,13
Therefore, a comprehensive therapeutic approach includes restric-
tion from endurance and high intensity sports, medical therapy
(including antiarrhythmic agents and prognostic medications in
patients with LV systolic impairment) and ICD implantation, where
indicated. Ventricular tachycardia ablation may also be utilized to
good effect, as seen here where our patient experienced multiple
ICD-treated arrhythmias despite optimized medical therapy.
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Table 1 Minimum set of genes implicated in the development of arrhythmogenic cardiomyopathy
Gene Protein type Mutation type
BLC2-Associated Athanogene 3 (BAG3) Chaperone Truncating and missense
Desmin Intermediate filament Truncating and missense
Desmocollin-2 (DSC2) Desmosomal Truncating and missense
Desmoglein-2 (DSG2) Desmosomal Truncating and missense
Desmoplakin (DSP) Desmosomal Truncating and missense
Filamin C (FLNC) Actin crosslink Truncating and missense
Junction Plakoglobin (JUP) Desmosomal Missense
LIM Domain Binding 3 (LBD3) Z-band Missense
Lamin A/C (LMNA) Nuclear envelope Truncating and missense
NK2 Homeobox 5 (NKX2-5) Homeobox Truncating and missense
Plakophilin-2 (PKP2) Desmosomal Truncating
Phospholamban (PLN) Calcium handing Missense, nonsense, and deletion
RNA-Binding Motif Protein 20 (RBM20) Splice factor Missense
Sodium Voltage-Gated Channel Alpha Subunit 5 (SCN5A) Sodium channel Mostly missense
Transmembrane Protein 43 (TMEM43) Nuclear envelope Missense
Adapted from HRS guidelines.1
Video 3 Vertical long axis (2-chamber) cardiovascular magnetic
resonance imaging at presentation.
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